Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.91% | 71.85% | 46.01% | -79.52% | -24.77% |
| Total Depreciation and Amortization | -81.68% | -79.25% | -50.80% | -85.04% | 80.06% |
| Total Amortization of Deferred Charges | -25.00% | -25.00% | -25.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -65.50% | -131.87% | -85.33% | 17.89% | 60.44% |
| Change in Net Operating Assets | 125.52% | 1,718.25% | -77.31% | 90.44% | -250.96% |
| Cash from Operations | 55.32% | 77.41% | -132.42% | 41.06% | -50.83% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 83.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 290.63% | 1,200.00% | 100.72% | 495.61% | 83.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -100.00% | -100.00% |
| Foreign Exchange rate Adjustments | -91.19% | -143.84% | 105.69% | -129.72% | 1,597.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 40.92% | 60.55% | -160.69% | -3.75% | -4.90% |